Zemaira
Zemaira
Zemaira is an alpha1 -proteinase inhibitor (A1 -PI) indicated for chronic augmentation and maintenance therapy in adults with A1 -PI deficiency and clinical evidence of emphysema.
Alpha1 antitrypsin (A1AT) deficiency, or Alpha-1 for short, is a hereditary and progressive condition that affects your lungs. It’s passed down from parent to child through their genes.
Zemaira was proven in clinical trials to raise and maintain levels of the Alpha-1 protein.
Administration Information
Zemaira is an intravenous infusion that generally takes about 15 to 30 minutes. Glassia is administered weekly, and dosing is weight based.
Potential Side Effects
In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.
For a full list of potential side effects, please see the Important Safety Information and Medication Guide on the Zemaira website.
Helpful Resources
Patient Forms
Before you attend your first appointment at Omega Health, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices and Patient Rights and Responsibilities are for reference only. Please contact us if you have any questions!
Patient Consent Form
Print & Sign
HIPAA Privacy Authorization Form
Print & Sign
Notice of Privacy Practice
Read
Patient Rights and Responsibilities
Read
Appointment Lateness and Cancelation
Read
